IONTAS identifies novel SARS-CoV-2 neutralising antibodies
IONTAS and FairJourney Biologics, leaders in the discovery and optimisation of fully human antibodies, have announced the identification of neutralizing antibodies, which bind to multiple emerging SARS-CoV-2 variants. The results, generated from a combination of phage display technology and B-cell receptor repertoire sequencing of hospitalized COVID-19 patients, have identified potent neutralizing antibodies with distinct mechanisms of […]
